Trials / Completed
CompletedNCT02263833
An Observational, Prospective, Safety Study of Mircera (Monopegylated Epoetin Beta) in Clinical Practice
Post Marketing Surveillance of Mircera®
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 748 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This national study was a post-marketing surveillance study conducted in Korea from 29 August 2008 to 28 August 2012 to meet local regulatory requirements for Mircera (monopegylated-epoetin beta). Prospective participant-based data collection was evaluated for safety/risk assessments and effectiveness. No specific study-related procedures are required. Participants were to be followed up as long as possible at the physician's discretion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mircera | Participants received Mircera according to individualized physician-prescribed regimen. |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2012-08-01
- Completion
- 2012-08-01
- First posted
- 2014-10-13
- Last updated
- 2016-09-07
- Results posted
- 2016-07-28
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02263833. Inclusion in this directory is not an endorsement.